This page shows the latest Oesophageal cancer news and features for those working in and with pharma, biotech and healthcare.
Small cell lung cancer accounts for 15% of all lung cancers and has a poor prognosis. ... tract cancer, oesophageal cancer, gastric and gastroesophageal cancer, cervical cancer, ovarian cancer, endometrial cancer, and other solid tumours.
The second indication is in colorectal cancer, targeting unresectable, advanced or recurrent high microsatellite instability (MSI-H) colorectal cancer. ... In the US alone, it is indicated for cancers including melanoma, non-small cell lung cancer,
Merck &Co’s – known as MSD outside the US and Canada – Keytruda has received an approval from the US Food and Drug Administration (FDA) for the treatment of advanced oesophageal cancer. ... status. “There have been few advances in improving
The US regulator will review the combo treatment for the first-line treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer (GEJC) or oesophageal adenocarcinoma (EAC). ... free survival (PFS) in patients with
such as stage III NSCLC and locally advanced oesophageal cancer. ... On top of these studies, tiragolumab is being evaluated in metastatic oesophageal squamous cancer and cervical cancer.
The US Food and Drug Administration (FDA) has already approved Opdivo for second-line advanced oesophageal cancer treatment, giving the immunotherapy a green light in June. ... Opdivo’s main rival in the oesophageal cancer setting is Merck &Co’s (MSD)
More from news
Approximately 6 fully matching, plus 19 partially matching documents found.
The company’s biggest play last year was licensing Daiichi Sankyo’s cancer candidate trastuzumab deruxtecan for an eyewatering. ... Other important read-outs in first-line kidney, oesophageal and gastric cancer are also due this year, as well as
has just achieved a landmark approval in China for its own ‘home-grown’ cancer medicine. ... Tislelizumab is in global phase III trials in a number of tumour types, including non-small cell lung cancer, hepatocellular carcinoma and oesophageal
Acquisition of royalty rights. $1, 140. Blueprint Medicines/ Roche. Small molecules targeting kinases for cancer immunotherapy. ... Collaboration – marketing &distribution. $171. AVEO Oncology/ CANbridge Life Sciences. AV-203; ErbB3 (HER3) inhibitory
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...